{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:07:40Z","timestamp":1788793660640,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with haematological or oncological malignancies are at increased risk of severe infections. Vaccination is a key preventive strategy and is recommended by National Immunization Technical Advisory Groups (NITAGs). Yet, vaccination rates in this population remain improvable. This project aimed to evaluate and enhance vaccine uptake in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pre- and post-observational study at the University Hospital Cologne in Germany to assess vaccination status over a 1.5-year intervention. Relevant infections included COVID-19, influenza, herpes zoster, pneumococci and RSV. The campaign included patient education, staff training, on-site vaccination, and targeted promotional efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 749 patients were included (n\u2009=\u2009398 in 2023, n\u2009=\u2009351 in 2025). Overall vaccination rates increased from 43 to 49%, while COVID-19 vaccine coverage remained above 90%. Notable increases were observed for influenza (37% to 48%), pneumococcal (16% to 36%), and herpes zoster (22% to 33%) vaccines. The proportion of patients fully vaccinated according to public health recommendations rose from 6 to 16%, whereas those completely unvaccinated remained low (4% to 6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Focused vaccination campaigns can effectively increase vaccine uptake in patients with cancer; however, the proportion of individuals vaccinated per recommended schedule remains low. Future research should investigate barriers and reasons for vaccine refusal to guide more targeted interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-026-29157-4","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:55:37Z","timestamp":1788789337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of an on-site vaccination campaign for patients with cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Theresa","family":"Markus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Eitze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Fl\u00fcmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"G\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"K\u00f6llges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Langerbeins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Leckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lehnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Mechtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rybniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Salmanton-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Steinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-2503","authenticated-orcid":false,"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"6","key":"29157_CR1","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","volume":"29","author":"CT Rieger","year":"2018","unstructured":"Rieger CT, Liss B, Mellinghoff S, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol: Official J Eur Society Med Oncol. 2018;29(6):1354\u201365.","journal-title":"Ann Oncol: Official J Eur Society Med Oncol"},{"issue":"5","key":"29157_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","volume":"12","author":"V Piechotta","year":"2022","unstructured":"Piechotta V, Mellinghoff SC, Hirsch C, et al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022;12(5):86.","journal-title":"Blood Cancer J"},{"issue":"6","key":"29157_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdy154","volume":"29","author":"T Weber","year":"2018","unstructured":"Weber T, Ljungman P. Stringent vaccination of cancer patients: is it that important? Ann Oncol: Official J Eur Society Med Oncol. 2018;29(6):1348\u20139.","journal-title":"Ann Oncol: Official J Eur Society Med Oncol"},{"key":"29157_CR4","doi-asserted-by":"crossref","unstructured":"R\u00fcthrich MM, Giesen N, Mellinghoff SC, et al. Cellular immune response after vaccination in patients with cancer-review on past and present experiences. Vaccines. 2022;10(2).","DOI":"10.3390\/vaccines10020182"},{"issue":"2","key":"29157_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40121-021-00433-7","volume":"10","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Chen Y, Yu K, et al. Fatal infections among cancer patients: a population-based study in the United States. Infect Dis Ther. 2021;10(2):871\u201395.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"29157_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168.","journal-title":"J Hematol Oncol"},{"key":"29157_CR7","unstructured":"Robert Koch-Institut. Beschluss und wissenschaftliche Begr\u00fcndung f\u00fcr die Erweiterung der Indikationsimpfempfehlung zur Herpes-zoster-Impfung mit dem adjuvantierten Subunit-Totimpfstoff f\u00fcr Personen \u2265 18 Jahre mit einem erh\u00f6hten Risiko, an Herpes zoster zu erkranken. 2025."},{"key":"29157_CR8","unstructured":"Robert Koch-Institut. Impfquoten in Deutschland \u2013 aktuelle Ergebnisse aus dem RKI-Impfquotenmonitoring. 2025."},{"key":"29157_CR9","unstructured":"RKI. Epidemiologisches Bulletin 49\/2022: Impfquoten bei Erwachsenen in Deutschland \u2013 Aktuelles aus der KV-Impfsurveillance. 2022."},{"issue":"1","key":"29157_CR10","doi-asserted-by":"publisher","first-page":"2543167","DOI":"10.1080\/21645515.2025.2543167","volume":"21","author":"E Ortiz-Prado","year":"2025","unstructured":"Ortiz-Prado E, Su\u00e1rez-Sangucho IA, Vasconez-Gonzalez J, et al. Pandemic paradox: how the COVID-19 crisis transformed vaccine hesitancy into a two-edged sword. Hum Vaccin Immunother. 2025;21(1):2543167.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"29157_CR11","first-page":"1","volume":"25","author":"S Impfkommission","year":"2025","unstructured":"Impfkommission S. Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut. Epid Bull. 2025;25(4):1\u201375.","journal-title":"Epid Bull"},{"issue":"6","key":"29157_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/21645515.2018.1445446","volume":"14","author":"M Bosaeed","year":"2018","unstructured":"Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother. 2018;14(6):1311\u201322.","journal-title":"Hum Vaccin Immunother"},{"issue":"14","key":"29157_CR13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(14):1699\u2013721.","journal-title":"J Clin Oncol"},{"issue":"44","key":"29157_CR14","first-page":"743","volume":"110","author":"U Theidel","year":"2013","unstructured":"Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals. Dtsch Arztebl Int. 2013;110(44):743\u201350.","journal-title":"Dtsch Arztebl Int"},{"key":"29157_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2022.05.029","volume":"172","author":"AS Mai","year":"2022","unstructured":"Mai AS, Lee ARYB, Tay RYK, et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022;172:65\u201375.","journal-title":"Eur J Cancer"},{"issue":"7","key":"29157_CR16","doi-asserted-by":"publisher","first-page":"e0004756","DOI":"10.1371\/journal.pgph.0004756","volume":"5","author":"H Melchinger","year":"2025","unstructured":"Melchinger H, Belgaumi SM, Ahmed N, et al. Change in influenza vaccine uptake among adults in the United States from May 2020 to October 2024. PLoS Glob Public Health. 2025;5(7):e0004756.","journal-title":"PLoS Glob Public Health"},{"issue":"6","key":"29157_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1037\/hea0001354","volume":"43","author":"D Holford","year":"2024","unstructured":"Holford D, Schmid P, Fasce A, et al. The empathetic refutational interview to tackle vaccine misconceptions: four randomized experiments. Health Psychol. 2024;43(6):426\u201337.","journal-title":"Health Psychol"},{"issue":"3","key":"29157_CR18","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.clml.2022.12.003","volume":"23","author":"MA Thompson","year":"2023","unstructured":"Thompson MA, Boccadoro M, Leleu X, et al. Rates of influenza and pneumococcal vaccination and correlation with survival in multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2023;23(3):e171\u201381.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"29157_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/cid\/civ803","volume":"62","author":"A Shigayeva","year":"2016","unstructured":"Shigayeva A, Rudnick W, Green K, et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62(2):139\u201347.","journal-title":"Clin Infect Dis"},{"key":"29157_CR20","first-page":"3","volume":"50","author":"T Rieck","year":"2024","unstructured":"Rieck T, Steffen A, Feig M, et al. Impfquoten in Deutschland \u2013 aktuelle Ergebnisse aus dem RKI-Impfquotenmonitoring. Epidemiologisches Bulletin. 2024;50:3\u201310.","journal-title":"Epidemiologisches Bulletin"},{"issue":"26","key":"29157_CR21","first-page":"466","volume":"119","author":"TR Kiderlen","year":"2022","unstructured":"Kiderlen TR, Trostdorf K, Delmastro N, et al. Raising Immunization Rates Among Cancer Patients. Deutsches Arzteblatt international. 2022;119(26):466\u20137.","journal-title":"Deutsches Arzteblatt international"},{"issue":"4","key":"29157_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00103-019-02900-6","volume":"62","author":"C Betsch","year":"2019","unstructured":"Betsch C, Schmid P, Korn L, et al. Impfverhalten psychologisch erkl\u00e4ren, messen und ver\u00e4ndern. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2019;62(4):400\u20139.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"issue":"12","key":"29157_CR23","first-page":"813","volume":"32","author":"E Niederstein","year":"2024","unstructured":"Niederstein E, Underwood J, de Wit M, et al. Streptococcus pneumoniae and influenza vaccination rates in oncological patients \u2014 data from Germany. Support Care Cancer. 2024;32(12):813.","journal-title":"Support Care Cancer"},{"key":"29157_CR24","first-page":"3","volume":"39","author":"J Schlaberg","year":"2023","unstructured":"Schlaberg J, Vygen-Bonnet S, Falman A, et al. Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen \u2265 60 Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. Epidemiologisches Bulletin. 2023;39:3\u201344.","journal-title":"Epidemiologisches Bulletin"},{"issue":"22","key":"29157_CR25","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med"},{"key":"29157_CR26","doi-asserted-by":"crossref","unstructured":"Krasselt M, Wagner U, Seifert O. Influenza, pneumococcal and herpes zoster vaccination rates in patients with autoimmune inflammatory rheumatic diseases. Vaccines. 2023;11(4).","DOI":"10.3390\/vaccines11040760"},{"key":"29157_CR27","unstructured":"Rieck T, Lottes M, Feig M, et al. Inanspruchnahme von Routineimpfungen in Deutschland - Ergebnisse aus der KV- Impfsurveillance."},{"key":"29157_CR28","doi-asserted-by":"publisher","first-page":"127465","DOI":"10.1016\/j.vaccine.2025.127465","volume":"62","author":"AL Wagner","year":"2025","unstructured":"Wagner AL, Floyd C. Impact of shingles vaccine tolerability on initiation and completion of the two-dose series in adults 50 years and older. Vaccine. 2025;62:127465.","journal-title":"Vaccine"},{"key":"29157_CR29","unstructured":"Robert Koch-Institut. VacMap \u2013 Dashboard zum Impfgeschehen in Deutschland. 2026. https:\/\/www.rki.de\/vacmap."},{"issue":"14","key":"29157_CR30","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.vaccine.2015.02.029","volume":"33","author":"W Poeppl","year":"2015","unstructured":"Poeppl W, Lagler H, Raderer M, et al. Influenza vaccination perception and coverage among patients with malignant disease. Vaccine. 2015;33(14):1682\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"29157_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.17269\/s41997-022-00693-x","volume":"114","author":"T Santavicca","year":"2023","unstructured":"Santavicca T, Ngov C, Frounfelker R, et al. COVID-19 vaccine hesitancy among young adults in Canada. Can J Public Health. 2023;114(1):10\u201321.","journal-title":"Can J Public Health"},{"key":"29157_CR32","doi-asserted-by":"publisher","first-page":"719665","DOI":"10.3389\/fpubh.2021.719665","volume":"9","author":"SK Syan","year":"2021","unstructured":"Syan SK, Gohari MR, Levitt EE, et al. COVID-19 vaccine perceptions and differences by sex, age, and education in 1,367 community adults in Ontario. Front Public Health. 2021;9:719665.","journal-title":"Front Public Health"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-29157-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-29157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-29157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:09:40Z","timestamp":1788790180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-29157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["29157"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-29157-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to \u00a7 15 and 6 of the Data Protection Act of North Rhine-Westphalia (Cologne), retrospective analysis and anonymised reporting of patient data without informed consent are appropriate. The study was reviewed and approved by the Ethics Committee of the Medical Faculty of Cologne University (Approval Number: [25\u20131242-retro]; Date: [10.07.2025]).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read the manuscript and agreed to publish it.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS has received research grants by the Ministry of Education and Research (BMBF), the Medical Faculty of the University of Cologne, Basilea Pharmaceutica, Noscendo, Scynexis \u2013 all paid to his institution; has received speaker honoraria by AbbVie, Akademie f\u00fcr Infektionsmedizin, Forum f\u00fcr Medizinische Fortbildung, Mundipharma, Hikma, Lilly and Pfizer; has served on advisory boards for Kite-Gilead, has been a consultant to AiCuris, Basilea, Gilead, Mundipharma, Shionogi, Alvea and Micron Research; has received travel grants by Page Medical. JSG has received speaker honoraria from AstraZeneca, Gilead, Pfizer, and Menarini, and has been a member of an advisory board for Pfizer, outside of the submitted work. SCM has received research grants by the EKFS, by DZIF, and the Medical Faculty of the University of Cologne; she has received speaker honoraria by Akademie f\u00fcr \u201cInfektionsmedizin\u201d, AstraZeneca, Karo, Gilead, and Pfizer; she has been a consultant to Octapharma. UH has received honoraria from Gilead and Pfizer.OAC reports institutional grants or contracts from iMi, iHi, DFG, BMFTR, DZIF, EU-DG RTD, G-BA, Cidara, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, AiCuris, Basilea, Cidara, Elion, Gilead, GSK, IQVIA, Janssen, MedPace, Menarini, Melinta, Mundipharma, Octapharma, Pardes, Pfizer, PSI, Scynexis, Seqirus, Shionogi; Speaker honoraria from Abbott, Abbvie, Hikma, AstraZeneca, Asahi Kasei, Gilead, GSK, Knight, InfectoPharm, Ipsen, Medscape\/WebMD, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, Vitis; Participation on a DRC, DSMB, DMC, or advisory board for AstraZeneca, Cidara, IQVIA, Janssen, MedPace, Melinta, PSI, Pulmocide, Vedanta.All remaining authors have nothing to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"2540"}}